Patient and Clinician-Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD-Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO-SCALP Study

The interim analysis of the PRO-SCALP study evaluated the effectiveness and patient satisfaction of CAL/BDP PAD-cream in treating mild-to-moderate scalp psoriasis in 134 adult patients across Germany, Spain, and the UK. The study found high treatment satisfaction, with significant improvements in quality of life and reduction in symptoms such as itching. Patients with higher adherence (VAS 80−100) experienced better outcomes compared to those with lower adherence (VAS <80). The cream was well-received due to its ease of use and favorable cosmetic properties, enhancing patient compliance. Notably, 77.9% of patients achieved clear or almost clear skin, and 81.5% had a significant reduction in psoriasis severity scores. The treatment also improved psychosocial outcomes, including self-esteem and sleep quality. Despite the lack of a control group, the findings suggest CAL/BDP PAD-cream is a promising treatment for scalp psoriasis, with further long-term studies needed to confirm these results.